Scynex­is takes out $60M loan ahead of ex­pect­ed ap­proval; Com­pass Ther­a­peu­tics ac­quires new bis­pe­cif­ic an­ti­body in buy­out

As the PDU­FA date for their vagi­nal yeast in­fec­tions quick­ly ap­proach­es, Scynex­is is tak­ing out a loan to en­sure it can hit the ground run­ning for a po­ten­tial com­mer­cial launch.

Scynex­is closed terms on a $60 mil­lion loan with Her­cules Cap­i­tal and Sil­i­con Val­ley Bank, the New Jer­sey biotech an­nounced Fri­day, with its ibrex­a­fungerp can­di­date set for a June 1 PDU­FA. Ap­proval of the pro­gram is an­tic­i­pat­ed, the com­pa­ny said, af­ter which the oral an­ti­fun­gal will be brand­ed as Brex­afemme.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER